Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

University of Alberta

$898,876.00

Discovery and Development of Brain-Sparing Inhibitors of Succinyl-CoA:3-Ketoacid CoA Transferase

EF 2021-22

Résumé
Our bodies rely on 3 major fuel sources we obtain from the food we eat; fats, sugars, and protein. However, during starvation our livers make a 4th fuel source that our organs (brain, heart, and muscle are the main users) can use to make energy, the ketone body. Past research has heavily focused on understanding the regulation of fat, sugar, and protein metabolism in health, and how they malfunction in various diseases such as obesity and diabetes. The regulation of ketone body metabolism in health and disease has received much less attention. However, exciting data in our lab has shown that decreasing the muscle's ability to burn ketone bodies for energy improves blood sugar control in obesity/diabetes. In addition, we have identified an old-group of drugs previously used to treat psychoses, which are able to decrease the ability of the muscle to burn ketone bodies for energy. Unfortunately, this old group of drugs is used less frequently for treating psychoses, due to the development of next generation anti-psychotic drugs, despite this old group of drugs being significantly cheaper. Importantly, this old group of drugs also appears to improve blood sugar control in obesity, but does have some brain-related side effects (e.g. drowsiness, dizziness, etc.) that may hinder its use as a therapy for diabetes. Thus, the goal of our research is to use both pharmaceutical science and chemistry methods to develop new drugs that are similar to these old group of drugs for psychoses, but are modified in a manner where they cannot reach the brain. We believe these new drugs may represent an exciting new treatment option to lower blood sugar levels in people with diabetes.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
443699
Name
Ussher John R
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Discovery and Development of Brain-Sparing Inhibitors of Succinyl-CoA:3-Ketoacid CoA Transferase
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$898,876
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Chemical Synthesis; Ketone Body Oxidation; Molecular Modeling; Preclinical Drug Development; Structure-Guided Drug Design; Succinyl Coa:3-Ketoacid Coa Transferase
Abstract
Our bodies rely on 3 major fuel sources we obtain from the food we eat; fats, sugars, and protein. However, during starvation our livers make a 4th fuel source that our organs (brain, heart, and muscle are the main users) can use to make energy, the ketone body. Past research has heavily focused on understanding the regulation of fat, sugar, and protein metabolism in health, and how they malfunction in various diseases such as obesity and diabetes. The regulation of ketone body metabolism in health and disease has received much less attention. However, exciting data in our lab has shown that decreasing the muscle's ability to burn ketone bodies for energy improves blood sugar control in obesity/diabetes. In addition, we have identified an old-group of drugs previously used to treat psychoses, which are able to decrease the ability of the muscle to burn ketone bodies for energy. Unfortunately, this old group of drugs is used less frequently for treating psychoses, due to the development of next generation anti-psychotic drugs, despite this old group of drugs being significantly cheaper. Importantly, this old group of drugs also appears to improve blood sugar control in obesity, but does have some brain-related side effects (e.g. drowsiness, dizziness, etc.) that may hinder its use as a therapy for diabetes. Thus, the goal of our research is to use both pharmaceutical science and chemistry methods to develop new drugs that are similar to these old group of drugs for psychoses, but are modified in a manner where they cannot reach the brain. We believe these new drugs may represent an exciting new treatment option to lower blood sugar levels in people with diabetes.
Competitiondate
202104
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Ussher, John R
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $898,876~ $0~